Ataraxis AI, a NYC-based AI precision medicine company, raised $20.4M in Series A funding.
The round was led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures, Obvious Ventures and angel investors including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus, and others.
The company intends to use the funds to expand operations and its development efforts.
Led by Jan Witowski, MD, PhD, and Krzysztof Geras, Ataraxis is an AI precision medicine company empowering patient outcomes through artificial intelligence. It is addressing issues in cancer prognosis and treatment selection through foundation models and multi-modal data. Its first clinically validated offering, Ataraxis Breast, is an AI-native prognostic/predictive platform for breast cancer and provides greater accuracy than standard of care genomic assays.
Ataraxis AI also announced its Clinical Advisory Board including: Dr. Francisco Esteva (Chief of Hematology and Medical Oncology at Northwell Lenox Hill), Dr. Lajos Pusztai (Co-Leader Genetics, Genomics and Epigenetics Program at Yale Cancer Center), Dr. Adam Brufsky (Co-Director of the Cancer Therapeutics Program at the UPMC Hillman Cancer Center), and Dr. Freya Schnabel (Director of Breast Surgery, NYU). These additions joined Yann LeCun, PhD, Chief AI Scientist at Meta and Turing Award Laureate, who serves as the company’s AI advisor.
